CLEVELAND, Ohio — The director of the Cleveland Clinic Lerner Research Institute’s Genomic Medicine Institute has been appointed to a federal advisory committee on genetics.
Dr. Charis Eng will advise the U.S. Department of Health and Human Services on the medical, ethical, legal and social implications of integrating genetic technologies into clinical and public health practice, according to a statement from the Cleveland Clinic. Eng has been appointed to a three-and-a-half-year term on HHS Secretary Kathleen Sebelius’ Advisory Committee on Genetics, Health and Society.
Hailed as a pioneer in the field of cancer genetics, Eng grew up in Singapore and the United Kingdom before entering the University of Chicago at age 16. After completing her degree at the Pritzker School of Medicine, she specialized in internal medicine at Beth Israel Hospital in Boston and trained in medical oncology at Harvard’s Dana-Farber Cancer Institute. She joined the Cleveland Clinic in 2005. She has published more than 300 peer-reviewed papers in various medical journals.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“The field of genetics is a rapidly evolving discipline,” said Eng. “Furthering our understanding and identification of genes will ultimately improve health care. I am honored to be selected to serve on this committee.”
